Lipoid pneumonia
For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Synonyms and keywords: Lipid pneumonia; Paraffinoma; Cholesterol pneumonia; Lipid granulomatosis; Golden pneumonia; Endogenous lipoid pneumonia; Exogenous lipoid pneumonia.
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
In 1925, G. F. LAUGHLEN, M.D. was the first physician to describe lipoid pneumonia. He first interacted with the disease by routine autopsy at the Toronto, Ontario hospital for sick children. He described grayish red nodules at the autopsy with three types of exudates, found out mononuclear cells which were unexpected in the exudates. In 1949 McDonald et al described endogenous lipoid pneumonia for the first time. He observed so-called “obstructive pneumonia” in patients with lung neoplasms. In September 2019, there was an outbreak of lipoid pneumonia related to vaping. it was then reported to be because of vitamin E soluble in THC e-cigarette juice. Lipoid pneumonia may be classified according to source of the lipid exposure into 2 subtypes: Exogenus, more common type reported, due to aspiration or inhalation of fatty substance, and endogenus, due to obstructive pneumonia.lipoid pneumonia parthenogenesis is different in its two sub-types: Exegenous form:it is understood that exogenus lipoid pneumonia is the result of chronic body reaction to fatty substance in the alveol. Lipid reaches alveoli by aspiration or inhalation. Some mineral oils can cause lung injuries such as gasoline. Mineral oils can enter the tracheobronchial tree without causing cough reflex which will bother mucociliary transport system chronically. Injected lipids mechanism of further producing lipid pneumonia is more complicated. As the lipid goes inside the alveoli, it is trapped and hard to expectorate, this condition may be worsen by associated neurological and gastrointestinal disorders affecting swallowing or cough. Lipids in alveoli form emulsion and then consumed by macrophages via phagocytosis. Since the alveolar macrophages cannot metabolize consumed fatty substance, oil is repeatedly released into alveoli after death of these macrophages. The oil released, illicits a giant-cell granulomatosis reaction. Endogenous form: The pathogenesis of endogenous lipoid pneumonia is still not well understood however there are plenty of suggested mechanisms, endogenous lipoid pneumonia can be caused by transbronchial dissemination of cancer cell breakdown products. Poorly differentiated adenocarcinoma cells secreting mucin is the most common neoplastic reason. Another mechanism suggested is anoxic tissue injury stimulating various enzymes such as phospholipase and mono-oxygenases.Infection changes to endogenous lipid pneumonia is generally localized in airways because the souronding lung is already consolidated, limiting the spread of bacteria. On gross and microscopic histology well circumscribed, firm with prominent lymphatics on lung surface in exogenous typelipoid material (or empty spaces), inflammatory cells and young fibroblasts. Reactive endarteritis, marked alveolar lining cell hyperplasia. Lipid-laden foamy macrophages are seen.Vaping is a common cause of lipoid pneumonia. occupationally related lipoid pneumonia is seen in fire-eaters(caused by Kedran oil). some trivial habits such as: use of oil-based laxatives, lip balm, lip gloss petroleum jelly play a role in lipoid pneumonia development. siphoning various mineral oils such as diesel is another common risk factor especially in India may be another causetive factor.Lipod pneumonia must be differentiated from other diseases that cause Cough with basilar infiltrates, such as bacterial pneumonia, viral pneumonia, congestive heart failure, pulmonary fibrosis, and aspiration pneumonia. Exogenous lipoid pneumonia is usually misdiagnosed as community-acquired pneumonia. in patients at risk of aspiration early CT scan is very useful for further diagnosis of lipoid pneumonia. Since lipid-laden pneumonia is is very sensitive but may not be very specific, the diagnosis of exogenous lipoid pneumonia is based on the triad of: History of mineral oil ingestion or vaping, compatible radiological findings, and presence of intra-alveolar lipids and/or lipid-laden macrophages.The incidence and prevalence of lipoid pneumonia are underestimated. It is mostly because of similarities between pneumonias from different causes and lack of specific marker to distinguish pneumonias from each other. In 2019 there was an outbreak of vaping based pulmonary complications.Lipoid pneumonia pathogenicity is because of lipid aspiration. Common risk factors in the development of aspiration pneumonia include dysphagia, swallowing dysfunction, altered mental status, COPD, and hospitalization. Less common risk factors in the development of aspiration pneumonia include medications, esophageal motility disorders, vomiting, enteral feeding, oropharyngeal colonization, male sex, and smoking.There is insufficient evidence to recommend routine screening for lipoid pneumonia.Patients might present acutely with inflammation and cough, fever, and dyspnea. However, they might be asymptomatic and present with an incidental mass on radiographs. Owing to its nonspecific symptoms and radiological features, lipoid pneumonia often remains undiagnosed or diagnosis is delayed. The oil released illicits a giant-cell granulomatous reaction (hence also called lipid granulomatosis), chronic inflammation, and alveolar and interstitial fibrosis. Evolution of lesions with time has been described: Fresh lesions show alveolar infiltration by lipid-laden macrophages and almost normal alveolar walls and septa, and advanced lesions show larger vacuoles and inflammatory infiltrates in alveolar walls, bronchial walls and septa. Diagnostic Study of Choice: lipoid pneumonia is mainly diagnosed based on clinical presentation. The CURB-65 and the eCURB scoring systems are used to evaluate and predict mortality in patients with pneumonia. However, they are not helpful in aspiration pneumonia. History and Symptoms; Patients with exogenous lipoid pneumonia have a positive history of oil contaminating prescription, E-cigarette smoking, vaping, using oily laxative, or other oil related history. in some cases high susceptibility to aspiration must be considered. Common symptoms of aspiration pneumonia include: Chest pain, cough, fever, sweating, and shaking chills.Physical examination of lipoid pneumonia does not reveal any different feature and is usually mistaken with community acquired pneumonia (CAP). may reveal low grade fever or sometimes low body temperature, an increased respiratory rate, low blood pressure, a fast heart rate, or a low oxygen saturation, which is the amount of oxygen in the blood as indicated by either pulse oximetry or blood gas analysis. Patients who have difficulty breathing, who are confused, or who have cyanosis (blue-tinged skin) require immediate attention. Auscultation findings include lack of normal breath sounds, the presence of crackling sounds (rales), or increased loudness of whispered speech (whispered pectoriloquy) with areas of the lung that are stiff and full of fluid, called consolidation. Vital signs are useful in determining the severity of illness and have predictive values. However, a high degree of suspicion should be kept in elderly as the presentation could be subtle in them. Different laboratory tests might be used in patients with aspiration pneumonia. Sputum analysis including lipid laden macrophage, gram stain and culture must be done in patients with cough. ABG may show acute hypoxemia and decreased mixed venous oxygen saturation. CBC shows leukocytosis with left shift or leukopenia, anemia, or thrombocytopenia. There are some non-specific findings on ECG of a patient with lipoid pneumonia which include sinus tachycardia, minor nonspecific ST-segment or T-wave changes, right atrial enlargement, QRS abnormalities like right axis deviation, and presence of S1S2S3.Chest x-rays may be helpful in the diagnosis of aspiration pneumonia. Findings on an chest x-ray suggestive of aspiration pneumonia include lobar pneumonia, areas of opacity, unilateral consolidation, air bronchogram, or cavitation. In some cases, ultrasound is used for the diagnosis and follow-up of a patient with pneumonia, for a guided thoracocentesis and to quantify the amount of pleural effusion, however its benefits are not yet indicated for lipoid pneumonia. Chest CT scan might be used in patients with aspiration pneumonia if a chest x-ray is not conclusive. CT findings may include lobar consolidation, ground-glass opacities, bronchiectasis, atelectasis, pleural effusion, and consolidation. A chest CT can also help to assess reasons for therapy failure and complications, such as lung abscess, and pleural effusions. Chest MRI may be helpful in the diagnosis of lipoid pneumonia. Findings on MRI suggestive of lipoid aspiration pneumonia may differentiate disease from other forms of aspiration pneumonia. Other findings are: atelectasis, consolidation and opacities.Bronchoscopy with bronchoalveolar lavage is useful to obtain samples for finding lipid-laden macrophages. In some cases of lipoid pneumonia, transbronchial lung biopsy or even surgical biopsy may be required to determine the exact cause of lipoid pneumonia, specially in endogenous form. videofluoroscopic swallow study (VFSS) might be used to evaluate swallowing difficulties. Treatment of lipoid pneumonia is not well studied and published experience is only with case reports.Bronchoalveolar lavage (BAL) is both diagnostic and therapeutic procedure in lipoid pneumonia, specially in children. Surgery is not a common treatment for lipoid pneumonia, but if there is a high suspicion of cancer, it would be considered as a therapy plan. video-assisted thoracoscopic surgery (VATS) lobectomy, is the favored method for these interventions. Lipoid pneumonia can be prevented by cessation of underlying cause like E-cigarette smoking or lipid based medications.it is also preventable by preventing aspiration pneumonia. effective measures for the primary prevention of aspiration pneumonia include dietary habit changes, maintaining oral hygiene, postural maneuvers, and medications such as H2 antagonists, metoclopramide, mosapride, amantadine, or cilostazol. Lipoid pneumonia can be prevented by cessation of underlying cause like E-cigarette smoking or lipid based medications.it is also preventable by preventing aspiration pneumonia. effective measures for the primary prevention of aspiration pneumonia include dietary habit changes, maintaining oral hygiene, postural maneuvers, and medications such as H2 antagonists, metoclopramide, mosapride, amantadine, or cilostazol.
Historical Perspective
In 1925, G. F. LAUGHLEN, M.D. was the first physician to describe lipoid pneumonia. He first interacted with the disease by routine autopsy at the Toronto, Ontario hospital for sick children. He described grayish red nodules at the autopsy with three types of exudates, found out mononuclear cells which were unexpected in the exudates. In 1949 McDonald et al described endogenous lipoid pneumonia for the first time. He observed so-called “obstructive pneumonia” in patients with lung neoplasms.
Classification
Lipoid pneumonia may be classified according to source of the lipid exposure into 2 subtypes: Exogenus, more common type reported, due to aspiration or inhalation of fatty substance, and endogenus, due to obstructive pneumonia.
Pathophysiology
lipoid pneumonia parthenogenesis is different in its two sub-types: Exegenous form:it is understood that exogenus lipoid pneumonia is the result of chronic body reaction to fatty substance in the alveol. Lipid reaches alveoli by aspiration or inhalation. Some mineral oils can cause lung injuries such as gasoline. Mineral oils can enter the tracheobronchial tree without causing cough reflex which will bother mucociliary transport system chronically. Injected lipids mechanism of further producing lipid pneumonia is more complicated. As the lipid goes inside the alveoli, it is trapped and hard to expectorate, this condition may be worsen by associated neurological and gastrointestinal disorders affecting swallowing or cough. Lipids in alveoli form emulsion and then consumed by macrophages via phagocytosis. Since the alveolar macrophages cannot metabolize consumed fatty substance, oil is repeatedly released into alveoli after death of these macrophages. The oil released, illicits a giant-cell granulomatosis reaction. Endogenous form: The pathogenesis of endogenous lipoid pneumonia is still not well understood however there are plenty of suggested mechanisms, endogenous lipoid pneumonia can be caused by transbronchial dissemination of cancer cell breakdown products. Poorly differentiated adenocarcinoma cells secreting mucin is the most common neoplastic reason. Another mechanism suggested is anoxic tissue injury stimulating various enzymes such as phospholipase and mono-oxygenases.Infection changes to endogenous lipid pneumonia is generally localized in airways because the souronding lung is already consolidated, limiting the spread of bacteria. On gross and microscopic histology well circumscribed, firm with prominent lymphatics on lung surface in exogenous typelipoid material (or empty spaces), inflammatory cells and young fibroblasts. Reactive endarteritis, marked alveolar lining cell hyperplasia. Lipid-laden foamy macrophages are seen.
Causes
Vaping is a common cause of lipoid pneumonia. occupationally related lipoid pneumonia is seen in fire-eaters(caused by Kedran oil). some trivial habits such as: use of oil-based laxatives, lip balm, lip gloss petroleum jelly play a role in lipoid pneumonia development. siphoning various mineral oils such as diesel is another common risk factor especially in India may be another causetive factor.
Differentiating Lipoid pneumonia from Other Diseases
Lipod pneumonia must be differentiated from other diseases that cause Cough with basilar infiltrates, such as bacterial pneumonia, viral pneumonia, congestive heart failure, pulmonary fibrosis, and aspiration pneumonia. Exogenous lipoid pneumonia is usually misdiagnosed as community-acquired pneumonia. in patients at risk of aspiration early CT scan is very useful for further diagnosis of lipoid pneumonia. Since lipid-laden pneumonia is is very sensitive but may not be very specific, the diagnosis of exogenous lipoid pneumonia is based on the triad of: History of mineral oil ingestion or vaping, compatible radiological findings, and presence of intra-alveolar lipids and/or lipid-laden macrophages.
Epidemiology and Demographics
The incidence and prevalence of lipoid pneumonia are underestimated. It is mostly because of similarities between pneumonias from different causes and lack of specific marker to distinguish pneumonias from each other. In 2019 there was an outbreak of vaping based pulmonary complications.
Risk Factors
Lipoid pneumonia pathogenicity is because of lipid aspiration. Common risk factors in the development of aspiration pneumonia include dysphagia, swallowing dysfunction, altered mental status, COPD, and hospitalization. Less common risk factors in the development of aspiration pneumonia include medications, esophageal motility disorders, vomiting, enteral feeding, oropharyngeal colonization, male sex, and smoking.
Screening
There is insufficient evidence to recommend routine screening for lipoid pneumonia.
Natural History, Complications, and Prognosis
Patients might present acutely with inflammation and cough, fever, and dyspnea. However, they might be asymptomatic and present with an incidental mass on radiographs. Owing to its nonspecific symptoms and radiological features, lipoid pneumonia often remains undiagnosed or diagnosis is delayed. The oil released illicits a giant-cell granulomatous reaction (hence also called lipid granulomatosis), chronic inflammation, and alveolar and interstitial fibrosis. Evolution of lesions with time has been described: Fresh lesions show alveolar infiltration by lipid-laden macrophages and almost normal alveolar walls and septa, and advanced lesions show larger vacuoles and inflammatory infiltrates in alveolar walls, bronchial walls and septa
Diagnosis
Diagnostic Study of Choice
Lipoid pneumonia is mainly diagnosed based on clinical presentation. The CURB-65 and the eCURB scoring systems are used to evaluate and predict mortality in patients with pneumonia. However, they are not helpful in aspiration pneumonia.
History and Symptoms
Patients with exogenous lipoid pneumonia have a positive history of oil contaminating prescription, E-cigarette smoking, vaping, using oily laxative, or other oil related history. in some cases high susceptibility to aspiration must be considered. Common symptoms of aspiration pneumonia include: Chest pain, cough, fever, sweating, and shaking chills.
Physical Examination
Physical examination of lipoid pneumonia does not reveal any different feature and is usually mistaken with community acquired pneumonia (CAP). May reveal low grade fever or sometimes low body temperature, an increased respiratory rate, low blood pressure, a fast heart rate, or a low oxygen saturation, which is the amount of oxygen in the blood as indicated by either pulse oximetry or blood gas analysis. Patients who have difficulty breathing, who are confused, or who have cyanosis (blue-tinged skin) require immediate attention. Auscultation findings include lack of normal breath sounds, the presence of crackling sounds (rales), or increased loudness of whispered speech (whispered pectoriloquy) with areas of the lung that are stiff and full of fluid, called consolidation. Vital signs are useful in determining the severity of illness and have predictive values. However, a high degree of suspicion should be kept in elderly as the presentation could be subtle in them.
Laboratory Findings
Different laboratory tests might be used in patients with aspiration pneumonia. Sputum analysis including lipid laden macrophage, gram stain and culture must be done in patients with cough. ABG may show acute hypoxemia and decreased mixed venous oxygen saturation. CBC shows leukocytosis with left shift or leukopenia, anemia, or thrombocytopenia.
Electrocardiogram
There are some non-specific findings on ECG of a patient with lipoid pneumonia which include sinus tachycardia, minor nonspecific ST-segment or T-wave changes, right atrial enlargement, QRS abnormalities like right axis deviation, and presence of S1S2S3.
X-ray
Chest x-rays may be helpful in the diagnosis of aspiration pneumonia. Findings on an chest x-ray suggestive of aspiration pneumonia include lobar pneumonia, areas of opacity, unilateral consolidation, air bronchogram, or cavitation.
Echocardiography and Ultrasound
In some cases, ultrasound is used for the diagnosis and follow-up of a patient with pneumonia, for a guided thoracocentesis and to quantify the amount of pleural effusion. However its benefits are not yet indicated for lipoid pneumonia.
CT scan
A chest CT scan might be used in patients with aspiration pneumonia if a chest x-ray is not conclusive. CT findings may include lobar consolidation, ground-glass opacities, bronchiectasis, atelectasis, pleural effusion, and consolidation. A chest CT can also help to assess reasons for therapy failure and complications, such as lung abscess, and pleural effusions.
MRI
Chest MRI may be helpful in the diagnosis of lipoid pneumonia. Findings on MRI suggestive of lipoid aspiration pneumonia may differentiate disease from other forms of aspiration pneumonia. Other findings are: atelectasis, consolidation and opacities.
Other Imaging Findings
Bronchoscopy with bronchoalveolar lavage is useful to obtain samples for finding lipid-laden macrophages.
Other Diagnostic Studies
In some cases of lipoid pneumonia, transbronchial lung biopsy or even surgical biopsy may be required to determine the exact cause of lipoid pneumonia, specially in endogenous form. videofluoroscopic swallow study (VFSS) might be used to evaluate swallowing difficulties.
Treatment
Medical Therapy
Treatment of lipoid pneumonia is not well studied and published experience is only with case reports.
Interventions
Bronchoalveolar lavage (BAL) is both diagnostic and therapeutic procedure in lipoid pneumonia, specially in children.
Surgery
Surgery is not a common treatment for lipoid pneumonia, but if there is a high suspicion of cancer, it would be considered as a therapy plan. video-assisted thoracoscopic surgery (VATS) lobectomy, is the favored method for these interventions.
Primary Prevention
Lipoid pneumonia can be prevented by cessation of underlying cause like E-cigarette smoking or lipid based medications.it is also preventable by preventing aspiration pneumonia. effective measures for the primary prevention of aspiration pneumonia include dietary habit changes, maintaining oral hygiene, postural maneuvers, and medications such as H2 antagonists, metoclopramide, mosapride, amantadine, or cilostazol.
Secondary Prevention
Lipoid pneumonia can be prevented by cessation of underlying cause like E-cigarette smoking or lipid based medications.it is also preventable by preventing aspiration pneumonia. Effective measures for the primary prevention of aspiration pneumonia include dietary habit changes, maintaining oral hygiene, postural maneuvers, and medications such as H2 antagonists, metoclopramide, mosapride, amantadine, or cilostazol.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
In 1925, G. F. LAUGHLEN, M.D. was the first physician to describe lipoid pneumonia. He first interacted with the disease by routine autopsy at the Toronto, Ontario hospital for sick children. He described grayish red nodules at the autopsy with three types of exudates, found out mononuclear cells which were unexpected in the exudates. In 1949 McDonald et al described endogenous lipoid pneumonia for the first time. He observed so-called “obstructive pneumonia” in patients with lung neoplasms.
Historical Perspective
Discovery
- In 1925,G. F. LAUGHLEN, M.D. was the first physician to describe exogenous lipoid pneumonia.[1]
- He first interacted to the disease by routine autopsy at the Toronto, Ontario hospital for sick children.
- He described grayish red nodules at the autopsy with three types of exudates, found out mononuclear cells which were unexpected in the exudates.
- All of his 4 observed cases underwent laxative and nasal drop therapy regimen.
- In 1949 McDonald et al described endogenous lipoid pneumonia for the first time.[2]
- He observed so called “obstructive pneumonia” in patients with lung neoplasms.[3]
Important landmark
Following are important landmark events that shows how aspiration pneumonia became an important entity of critical care:[4][5][3][6][7][8]
| Year | Events |
|---|---|
| 460 BC–380 BC | Hippocrates described pneumonia. |
| 1138–1204 AD | Maimonides wrote about pneumonia as “The basic symptoms which occur in pneumonia and which are never lacking are as follows: acute fever, sticking pleuritic pain in the side, short rapid breaths, serrated pulse, and cough.” |
| 1875 | Edwin Klebs identified bacteria in the airways of individuals who died from pneumonia. |
| 1848 | Carl Friedländer identified the two common bacteria such as Streptococcus pneumoniae and Klebsiella pneumoniae that cause pneumonia. |
| 1893 | Veillon was first to write about the role of anaerobic bacteria in aspiration pneumonia. |
| 1896 | Roentgen described x-rays. |
| 1918 | Sir William Osler, known as “the father of modern medicine,” appreciated the morbidity and mortality of pneumonia, describing it as the “captain of the men of death.” |
| 1927 | Smith was first to clearly show anaerobic bacterial growth in animal models suffered from aspiration pneumonia. |
| 1929 | Drinker and Shaw announced the invention of the iron lung during the polio epidemic. |
| 1985 | Specimens collected from patients with aspiration pneumonia were vastly cultured and it was called anaerobic bandwagon. |
Lipoid pneumonia outbreak
- During July and August 2019, five patients were identified at two hospitals in North Carolina with acute lung injury potentially associated with e-cigarette use.
- Patients were adults aged 18–35 years and all experienced several days of worsening dyspnea, nausea, vomiting, abdominal discomfort, and fever.
- All patients demonstrated tachypnea with increased work of breathing on examination, hypoxemia (pulse oximetry <90% on room air), and bilateral lung infiltrates on chest x-ray.
- All five patients shared history of recent use of marijuana oils or concentrates in e-cigarettes.[9]
- Thirty-three deaths confirmed due to vaping in 24 states of US, but lipoid pneumonia role in those mortalities was not proven.[10]
- The higher risk of lipoid pneumonia in THC vaping was then hypothesized to be due to usage of vitamin E in THC juice of e-cigarettes.[11]
- Vitamin E is a substance added to cannabis products to increase their central effect.
- It’s streaky and high solubility potential is said to be the cause of lipoid pneumonia.
|
{{#ev:youtube|https://www.youtube.com/watch?v=BtKbUpKeU_Q%7C500}} |
References
- ↑ Laughlen GF (July 1925). “Studies on Pneumonia Following Naso-Pharyngeal Injections of Oil”. The American Journal of Pathology. 1 (4): 407–414.1. PMC 1931653. PMID 19969662.
- ↑ McDONALD JR, HARRINGTON SW, CLAGETT OT (1949). “Obstructive pneumonitis of neoplastic origin; an interpretation of one form of so-called atelectasis and its correlation according to presence of absence of sputum”. J Thorac Surg. 18 (1): 97–112, disc., 122. PMID 18110247.
- ↑ 3.0 3.1 Marik PE, Careau P (1999). “The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study”. Chest. 115 (1): 178–83. PMID 9925081.
- ↑ Japanese Respiratory Society (2009). “Aspiration pneumonia”. Respirology. 14 Suppl 2: S59–64. doi:10.1111/j.1440-1843.2009.01578.x. PMID 19857224.
- ↑ Almirall J, Cabré M, Clavé P (2012). “Complications of oropharyngeal dysphagia: aspiration pneumonia”. Nestle Nutr Inst Workshop Ser. 72: 67–76. doi:10.1159/000339989. PMID 23052002.
- ↑ Cordier JF, Cottin V (2013). “Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis”. Eur Respir J. 42 (4): 916–23. doi:10.1183/09031936.00027913. PMID 23598958.
- ↑ Shi X, Zheng J, Yan T (2018). “Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia”. J Mol Model. 24 (4): 79. doi:10.1007/s00894-018-3613-z. PMID 29500665.
- ↑ Shen CF, Wang SM, Ho TS, Liu CC (2017). “Clinical features of community acquired adenovirus pneumonia during the 2011 community outbreak in Southern Taiwan: role of host immune response”. BMC Infect Dis. 17 (1): 196. doi:10.1186/s12879-017-2272-5. PMC 5341368. PMID 28270104.
- ↑ “Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR”.
- ↑ “Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR”.
- ↑ “CDC vaping illness investigation: Vitamin E acetate linked to THC may be to blame – CNN”.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Lipoid pneumonia may be classified according to source of the lipid exposure into 2 subtypes: Exogenous, more common type reported, due to aspiration or inhalation of fatty substance, and endogenous, due to obstructive pneumonia.
Classification
- Lipoid pneumonia may be classified according to source of the lipid exposure into 2 subtypes:[1][2]
| Lipoid pneumonia classification | |||||||||||||||||||||||||
| Exogenus: More common type reported, due to aspiration or inhalation of fatty substance. | Endogenus: Due to obstructive pneumonia. | ||||||||||||||||||||||||
| Type I | Type II | Type III | |||||||||||||||||||||||
- Endogenous pneumonia further divide into 3 subgroups:[3]
- Type I: Localized to the lung parenchyma distal to an airway obstructed by a tumor.
- Type II: Features of type I lipoid pneumonia and consecutively spreading to the adjacent segment whose airway is not affected.
- Type III: Features of type II lipoid pneumonia and spreading to isolated segments.
References
- ↑ BARON E (1950). “Lipoid pneumonia due to the use of mineral oil as a laxative”. Va Med Mon (1918). 77 (9): 448–50. PMID 15443468.
- ↑ Gondouin, A.; Manzoni, Ph.; Ranfaing, E.; Brun, J.; Cadranel, J.; Sadoun, D.; Cordier, J.F.; Depierre, A.; Dalphin, J.C. (1996). “Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France”. European Respiratory Journal. 9 (7): 1463–1469. doi:10.1183/09031936.96.09071463. ISSN 0000-0000.
- ↑ Tamura, A.; Hebisawa, A.; Fukushima, K.; Yotsumoto, H.; Mori, M. (1998). “Lipoid Pneumonia in Lung Cancer: Radiographic and Pathological Features”. Japanese Journal of Clinical Oncology. 28 (8): 492–496. doi:10.1093/jjco/28.8.492. ISSN 0368-2811.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Lipoid pneumonia pathogenesis is different in its two subtypes: Exogenous form is the result of chronic body reaction to fatty substance in the alveoli. Lipid reaches alveoli by aspiration or inhalation. Some mineral oils can cause lung injuries such as gasoline. Mineral oils can enter the tracheobronchial tree without causing cough reflex which will bother mucociliary transport system chronically. Injected lipids mechanism of further producing lipid pneumonia is more complicated. As the lipid goes inside the alveoli, it is trapped and hard to expectorate, this condition may be worsen by associated neurological and gastrointestinal disorders affecting swallowing or cough. Lipids in alveoli form emulsion and then consumed by macrophages via phagocytosis. Since the alveolar macrophages cannot metabolize consumed fatty substance, oil is repeatedly released into alveoli after death of these macrophages. The oil released, elicits a giant-cell granulomatosis reaction. Pathogenesis of endogenous form is still not well understood however there are plenty of suggested mechanisms, one saying that endogenous lipoid pneumonia can be caused by transbronchial dissemination of cancer cell breakdown products. Poorly differentiated adenocarcinoma cells secreting mucin is the most common neoplastic reason. Another mechanism suggested is anoxic tissue injury stimulating various enzymes such as phospholipase and monooxygenases. Infection changes to endogenous lipid pneumonia is generally localized in airways because the surrounding lung is already consolidated, limiting the spread of bacteria. On gross and microscopic histology will show well circumscribed, firm with prominent lymphatics on lung surface, inflammatory cells, and young fibroblasts. Reactive endarteritis and marked alveolar lining cell hyperplasia may also be seen. Lipid-laden foamy macrophages are part of pathology.
Pathophysiology
Exogenous lipoid pneumonia
The important pathophysiology aspects regarding exogenous lipoid pneumonia include:[1][2]
- It is understood that exogenous lipoid pneumonia is the result of chronic body reaction to fatty substance in the alveoli.
- Lipid reaches alveoli by aspiration or inhalation.
- Some mineral oils can cause lung injuries such as gasoline.
- Mineral oils can enter the tracheobronchial tree without causing cough reflex which will bother mucociliary transport system chronically.
- Injected lipids mechanism of further producing lipid pneumonia is more complicated:
- It is suggested that the lung is the first capillary bed encountered during circulation, bearing the majority of damage.
- As the lipid goes inside the alveoli, it is trapped and hard to expectorate, this condition may be worsen by associated neurological and gastrointestinal disorders affecting swallowing or cough.
- Lipids in alveoli form emulsion and then consumed by macrophages via phagocytosis.
- Since the alveolar macrophages cannot metabolize consumed fatty substance, oil is repeatedly released into alveoli after death of these macrophages.
- The oil released, elicits a giant-cell granulomatosis reaction:
- In fresh lesions, lipid-laden macrophages are seen.
- In advanced lesions larger vacuoles and inflammatory infiltrates are seen in alveolar and bronchial walls and septa.
- In oldest lesions fibrosis and parenchymal destruction around large lipid-containing vacuoles is seen.
- Staining can help demonstrating whether vacuoles are filled with lipid or not:
Endogenous lipoid pneumonia
The pathogenesis of endogenous lipoid pneumonia is still not well understood however there are plenty of suggested mechanisms:[3][4][5]
- Most proven mechanisms are:
- Retained epithelial secretion.
- Cell breakdown.
- Leakage from vessels.
- Prolonged hypoxia.
- Local oxygen and carbon dioxide tension.
- Endogenous lipoid pneumonia can be caused by transbronchial dissemination of cancer cell breakdown products.[6]
- Poorly differentiated adenocarcinoma cells secreting mucin is the most common neoplastic reason.
- Another mechanism suggested is anoxic tissue injury stimulating various enzymes such as phospholipase and mono-oxygenases.[7][8][9]
- These enzymes activation in turn cause modification of LDL cholesterol, enhancing lipid uptake by alveolar macrophages similar to atherogenesis.
- Infection changes to endogenous lipid pneumonia is generally localized in airways because the surrounding lung is already consolidated, limiting the spread of bacteria.[10]
Genetics
There is no genetic predisposition reported with lipoid pneumonia.
Associated Conditions
- Vaping is associated with exogenous lipoid pneumonia.[7][4]
- Fire eating is associated with exogenous lipoid pneumonia.
- Using oily laxative is associated with exogenous lipoid pneumonia.
- Pulmonary adenocarcinoma is associated with endogenous lipid pneumonia.
- Long lasting pulmonary granulomatosis diseases is associated with endogenous lipid pneumonia.
Gross Pathology
- Well circumscribed, firm with prominent lymphatics on lung surface in exogenous type.[11]
- Parenchymal consolidation in endogenous lipoid pneumonia produce a characteristic yellowish discoloration, hence called “golden pneumonia“.[12]

Microscopic Pathology
- Lipoid material (or empty spaces), inflammatory cells and young fibroblasts.[14]
- Reactive endarteritis, marked alveolar lining cell hyperplasia.
- Lipid-laden foamy macrophages


|
{{#ev:youtube|https://www.youtube.com/watch?v=nGi0udE5EI8%7C500}} |
References
- ↑ Guerguerian, Anne-Marie; Lacroix, Jacques (2000). “Pulmonary injury after intravenous hydrocarbon injection”. Paediatrics & Child Health. 5 (8): 471–472. doi:10.1093/pch/5.8.471. ISSN 1205-7088.
- ↑ Domej, Wolfgang; Mitterhammer, Heike; Stauber, Rudolf; Kaufmann, Peter; Smolle, Karl Heinz (2007). “Successful outcome after intravenous gasoline injection”. Journal of Medical Toxicology. 3 (4): 173–177. doi:10.1007/BF03160935. ISSN 1556-9039.
- ↑ Burke, M; Fraser, R (1988). “Obstructive pneumonitis: a pathologic and pathogenetic reappraisal”. Radiology. 166 (3): 699–704. doi:10.1148/radiology.166.3.3340764. ISSN 0033-8419.
- ↑ 4.0 4.1 “www.thoracic.org” (PDF).
- ↑ Cohen, Allen B.; Cline, Martin J. (1972). “In VitroStudies of the Foamy Macrophage of Postobstructive Endogenous Lipoid Pneumonia in Man1–3”. American Review of Respiratory Disease. 106 (1): 69–78. doi:10.1164/arrd.1972.106.1.69. ISSN 0003-0805.
- ↑ Tamura, A.; Hebisawa, A.; Fukushima, K.; Yotsumoto, H.; Mori, M. (1998). “Lipoid Pneumonia in Lung Cancer: Radiographic and Pathological Features”. Japanese Journal of Clinical Oncology. 28 (8): 492–496. doi:10.1093/jjco/28.8.492. ISSN 0368-2811.
- ↑ 7.0 7.1 Taki, Takao; Nakazima, Tomoko; Emi, Yohko; Konishi, Yohichi; Hayashi, Akira; Matsumoto, Makoto (1986). “Accumulation of surfactant phospholipids in lipid pneumonia induced with methylnaphthalene”. Lipids. 21 (9): 548–552. doi:10.1007/BF02534050. ISSN 0024-4201.
- ↑ Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff MW (1993). “Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms”. J Lipid Res. 34 (5): 703–17. PMID 8509711.
- ↑ Tölle, Angelika; Kolleck, Ingrid; Schlame, Michael; Wauer, Roland; Stevens, Paul A.; Rüstow, Bernd (1997). “Effect of hyperoxia on the composition of the alveolar surfactant and the turnover of surfactant phospholipids, cholesterol, plasmalogens and vitamin E”. Biochimica et Biophysica Acta (BBA) – Lipids and Lipid Metabolism. 1346 (2): 198–204. doi:10.1016/S0005-2760(97)00036-2. ISSN 0005-2760.
- ↑ Burke, M; Fraser, R (1988). “Obstructive pneumonitis: a pathologic and pathogenetic reappraisal”. Radiology. 166 (3): 699–704. doi:10.1148/radiology.166.3.3340764. ISSN 0033-8419.
- ↑ “Pathology Outlines – Lipoid pneumonia”.
- ↑ Gaerte, Scott C.; Meyer, Cristopher A.; Winer-Muram, Helen T.; Tarver, Robert D.; Conces, Dewey J. (2002). “Fat-containing Lesions of the Chest”. RadioGraphics. 22 (suppl_1): S61–S78. doi:10.1148/radiographics.22.suppl_1.g02oc08s61. ISSN 0271-5333.
- ↑ “Pulmonary Pathology”.
- ↑ “Pathology Outlines – Lipoid pneumonia”.
- ↑ Han, Chenghong; Liu, Lihai; Du, Shiping; Mei, Jianhua; Huang, Ling; Chen, Min; Lei, Yongliang; Qian, Junwen; Luo, Jianyong; Zhang, Meibian (2016). “Investigation of rare chronic lipoid pneumonia associated with occupational exposure to paraffin aerosol”. Journal of Occupational Health. 58 (5): 482–488. doi:10.1539/joh.16-0096-CS. ISSN 1341-9145.
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Vaping is a common cause of lipoid pneumonia. Occupationally related lipoid pneumonia is seen in fire-eaters(caused by Kedran oil). Some trivial habits such as: Use of oil-based laxatives, lip balm, lip gloss petroleum jelly play a role in lipoid pneumonia development. Siphoning various mineral oils such as diesel is another common risk factor especially in India may be another causetive factor.
Exogenous lipoid Pneumonia Causes
Common Causes
- Vaping is a common cause of lipoid pneumonia:[1][2][3]
- E-cigarets and vapes use an oily juice as their source.
- Heating the oil makes the smoke.
- They can be used as THC or other drug smoking material.
- There is a high association between THC or other highly concentrated oil juice material with lipoid pneumonia.
- Occupationally related lipoid pneumonia is seen in fire-eaters(caused by Kedran oil).[4][5]
Less common causes
- Some trivial habits such as:[6][7]
- Use of oil-based laxatives
- Lip balm
- Lip gloss
- Petroleum jelly
- Siphoning various mineral oils such as diesel is another common risk factor especially in India.
- Forceful animal fat feeding such as ‘Ghee’ is another common cause among Indians.
- Exogenous lipid could be aspirated through these mechanisms
Genetic causes
- There is no reported genetic causes for exogenous lipoid pneumonia.[8]
Aspiration causes
- Incompetent swallowing mechanism, such as in neurological disease (a common cause being strokes) or while a person is intoxicated.
- Iatrogenic causes such as general anaesthesia for an operation. Patients are therefore instructed to be “not permitted orally” (NPO) for at least four hours before surgery.
- Exogenous lipoid pneumonia could be an iatrogenic outcome of bronchoscopy with propylidone dye.
- Drug Side Effect:
Endogenous lipoid Pneumonia Causes
- Most common cause of endogenous lipoid pneumonia pre-existing conditions such as:[9][10][11][12][13][14][15]
- Endogenous lipid pneumonia is a direct consequence of bronchial obstruction:
- The main reason is non-small cell carcinoma.
- Endogenous lipid pneumonia can occure as manifestation of infection or other diseases with no obstruction.
- Endogenous lipoid pneumonia has been observed in association with pulmonary alveolar proteinosis.
- Alveolar proteinosis is filling the alveoli with protein and lipid resembling surfactant.
- It manifest as ground-glass capacities and crazy-paving pattern on CT scan
- Niemann-pick disease
- Sclerosing cholangitis
- Bronchiolitis oblitera
- Nercotizing granulomatosis
- Connective tissue disease
- Endogenous lipid pneumonia is a direct consequence of bronchial obstruction:

Causes by Organ System
| Cardiovascular | No underlying causes |
| Chemical/Poisoning | petroleum jelly |
| Dental | No underlying causes |
| Dermatologic | No underlying causes |
| Drug Side Effect | Oil based luxatives |
| Ear Nose Throat | No underlying causes |
| Endocrine | No underlying causes |
| Environmental | No underlying causes |
| Gastroenterologic | No underlying causes |
| Genetic | No underlying causes |
| Hematologic | No underlying causes |
| Iatrogenic | Oil based prescriptions |
| Infectious Disease | No underlying causes |
| Musculoskeletal/Orthopedic | No underlying causes |
| Neurologic | No underlying causes |
| Nutritional/Metabolic | No underlying causes |
| Obstetric/Gynecologic | No underlying causes |
| Oncologic | solid tumors |
| Ophthalmologic | No underlying causes |
| Overdose/Toxicity | No underlying causes |
| Psychiatric | No underlying causes |
| Pulmonary | No underlying causes |
| Renal/Electrolyte | No underlying causes |
| Rheumatology/Immunology/Allergy | No underlying causes |
| Sexual | No underlying causes |
| Trauma | No underlying causes |
| Urologic | No underlying causes |
| Miscellaneous | Vaping with oily juice |
References
- ↑ Gondouin, A.; Manzoni, Ph.; Ranfaing, E.; Brun, J.; Cadranel, J.; Sadoun, D.; Cordier, J.F.; Depierre, A.; Dalphin, J.C. (1996). “Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France”. European Respiratory Journal. 9 (7): 1463–1469. doi:10.1183/09031936.96.09071463. ISSN 0000-0000.
- ↑ Meltzer, E.; Guranda, L.; Perelman, M.; Krupsky, M.; Vassilenko, L.; Sidi, Y. (2005). “Lipoid pneumonia: A preventable form of drug-induced lung injury”. European Journal of Internal Medicine. 16 (8): 615–617. doi:10.1016/j.ejim.2005.06.014. ISSN 0953-6205.
- ↑ “Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR”.
- ↑ Kitchen, J M; O’Brien, D E; McLaughlin, A M (2008). “Perils of fire eating”. Thorax. 63 (5): 401–401. doi:10.1136/thx.2007.090001. ISSN 0040-6376.
- ↑ Seaton, A. (2010). “Lipoid pneumonia in a fire breather”. Occupational Medicine. 60 (5): 406–406. doi:10.1093/occmed/kqq094. ISSN 0962-7480.
- ↑ Spickard, Anderson (1994). “Exogenous Lipoid Pneumonia”. Archives of Internal Medicine. 154 (6): 686. doi:10.1001/archinte.1994.00420060122013. ISSN 0003-9926.
- ↑ Hadda, Vijay; Khilnani, Gopi C; Bhalla, Ashu S; Mathur, Sandeep (2009). “Lipoid pneumonia presenting as non resolving community acquired pneumonia: a case report”. Cases Journal. 2 (1): 9332. doi:10.1186/1757-1626-2-9332. ISSN 1757-1626.
- ↑ Lu M, Yan W, Zhu X, Zhu H (2019). “[Exogenous lipoid pneumonia induced by long-term usage of compound menthol nasal drops: a case report]”. Beijing Da Xue Xue Bao Yi Xue Ban. 51 (2): 359–361. PMID 30996383.
- ↑ Gaerte, Scott C.; Meyer, Cristopher A.; Winer-Muram, Helen T.; Tarver, Robert D.; Conces, Dewey J. (2002). “Fat-containing Lesions of the Chest”. RadioGraphics. 22 (suppl_1): S61–S78. doi:10.1148/radiographics.22.suppl_1.g02oc08s61. ISSN 0271-5333.
- ↑ Au, W.Y.; Lie, A.K.; Cheng, V.C.C.; Cheng, L.C.; Wang, E.P.; Wong, C.F. (2007). “Successful Lung Transplantation for Post-BMT Bronchiolitis Obliterans and Lipoid Pneumonia Associated with Atypical Mycobacterium and Aspergillosis Infection”. The Journal of Heart and Lung Transplantation. 26 (8): 870–872. doi:10.1016/j.healun.2007.05.015. ISSN 1053-2498.
- ↑ Berghaus, Thomas M; Haeckel, Thomas; Wagner, Theodor; von Scheidt, Wolfgang; Schwaiblmair, Martin G (2007). “Endogenous lipoid pneumonia associated with primary sclerosing cholangitis”. The Lancet. 369 (9567): 1140. doi:10.1016/S0140-6736(07)60530-3. ISSN 0140-6736.
- ↑ Nicholson, Andrew G.; Wells, Athol U.; Hooper, James; Hansell, David M.; Kelleher, Andrea; Morgan, Cliff (2002). “Successful Treatment of Endogenous Lipoid Pneumonia due to Niemann–Pick Type B Disease with Whole-Lung Lavage”. American Journal of Respiratory and Critical Care Medicine. 165 (1): 128–131. doi:10.1164/ajrccm.165.1.2103113. ISSN 1073-449X.
- ↑ Itoh, Yasushi; Segawa, Hidekazu; Kito, Katsuyuki; Hodohara, Keiko; Ishigaki, Hirohito; Sugihara, Hiroyuki; Fujiyama, Yoshihide; Ogasawara, Kazumasa (2009). “Lipoid pneumonia with chronic myelomonocytic leukemia”. Pathology – Research and Practice. 205 (2): 143–147. doi:10.1016/j.prp.2008.07.013. ISSN 0344-0338.
- ↑ Spalding, Steven J; Cambria, Marnie; Arkachaisri, Thaschawee (2009). “Distinguishing Wegener’s granulomatosis from necrotizing community acquired pneumonia: A case report and comparison of radiographic findings”. Pediatric Pulmonology. 44 (2): 195–197. doi:10.1002/ppul.20959. ISSN 8755-6863.
- ↑ Barta Z, Szabo GG, Bruckner G, Szegedi G (2001). “Endogenous lipoid pneumonia associated with undifferentiated connective tissue disease (UCTD)”. Med Sci Monit. 7 (1): 134–6. PMID 11208509.
- ↑ Katsumi, Hidenori; Tominaga, Masaki; Tajiri, Morihiro; Shimizu, Shigeki; Sakazaki, Yuki; Kinoshita, Takashi; Okamoto, Masaki; Kawayama, Tomotaka; Hoshino, Tomoaki (2016). “A case of lipoid pneumonia caused by inhalation of vaporized paraffin from burning candles”. Respiratory Medicine Case Reports. 19: 166–168. doi:10.1016/j.rmcr.2016.10.001. ISSN 2213-0071.
Differentiating Lipoid pneumonia from other Diseases

For the WikiDoc page for this topic, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Lipod pneumonia must be differentiated from other diseases that cause cough with basilar infiltrates, such as bacterial pneumonia, viral pneumonia, congestive heart failure, pulmonary fibrosis, and aspiration pneumonia. Exogenous lipoid pneumonia is usually misdiagnosed as community-acquired pneumonia. In patients at risk of aspiration early CT scan is very useful for further diagnosis of lipoid pneumonia. Since lipid-laden pneumonia is very sensitive but may not be very specific, the diagnosis of exogenous lipoid pneumonia is based on the triad of: History of mineral oil ingestion or vaping, compatible radiological findings, and presence of intra-alveolar lipids and/or lipid-laden macrophages.
Differentiating lipoid pneumonia from other Diseases
- Lipod pneumonia must be differentiated from other diseases that cause cough with basilar infiltrates, such as bacterial pneumonia, viral pneumonia, congestive heart failure, pulmonary fibrosis, and aspiration pneumonia.[1]
- Differentiating exogenous lipoid pneumonia from other diseases on the basis of radiologic features and specimen histologic features:[2][3][4][5][6][7]
- Exogenous lipoid pneumonia is usually misdiagnosed as community-acquired pneumonia.
- It is considered usually as the initial diagnosis that does not lead to appropriate therapy.
- In patients at risk of aspiration early CT scan is very useful for further diagnosis of lipoid pneumonia.
- Diagnosis is confirmed by detecting intra-alveolar lipid and lipid-laden macrophages.
- Specimens could be brought by:
- BAL (Broncho Alveolar Lavage)
- Transthoracic fine-needle aspiration cytology
- Biopsy from lesion
- Sputum examination has questionable reliability because lipid-laden macrophages in sputum have been demonstrated in the absence of lipoid pneumonia.
- BAL is widely available and the choice of specimen taking today.
- Frozen samples must be stained in order to determine the type of oil.
- Since lipid-laden pneumonia is is very sensitive but may not be very specific, the diagnosis of exogenous lipoid pneumonia is based on the following triad (based on order):
- History of mineral oil ingestion or vaping
- Compatible radiological findings
- Presence of intra-alveolar lipids and/or lipid-laden macrophages
| Diseases | Diagnostic tests | Physical Examination | Symptoms | Past medical history | Other Findings | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CT scan and MRI | EKG | Chest X-ray | Tachypnea | Tachycardia | Fever | Chest Pain | Hemoptysis | Dyspnea on Exertion | Wheezing | Chest Tenderness | Nasalopharyngeal Ulceration | Carotid Bruit | |||
| Pulmonary embolism |
|
|
|
✔ | ✔ | ✔ (Low grade) | ✔ | ✔ (In case of massive PE) | ✔ | – | – | – | – |
|
|
| Congestive heart failure |
|
✔ | ✔ | ✔ | – | – | ✔ | – | – | – | – |
|
| ||
| Percarditis |
|
|
|
✔ | ✔ | ✔ (Low grade) | ✔ (Relieved by sitting up and leaning forward) | – | ✔ | – | – | – | – |
|
|
| Pneumonia |
|
|
|
✔ | ✔ | ✔ | ✔ | – | ✔ | ✔ | – | – | – |
|
|
| Vasculitis |
|
|
✔ | ✔ | ✔ | ✔ | ✔ | ✔ | – | ✔ | ✔ | ✔ |
|
||
| Chronic obstructive pulmonary disease (COPD) |
|
|
✔ | ✔ | – | – | – | ✔ | ✔ | – | – | – |
|
| |
References
- ↑ Bell MM (2015). “Lipoid pneumonia: An unusual and preventable illness in elderly patients”. Can Fam Physician. 61 (9): 775–7. PMC 4569110. PMID 26371101.
- ↑ Parameswaran, K.; Anvari, M.; Efthimiadis, A.; Kamada, D.; Hargreave, F.e; Allen, C.j (2000). “Lipid-laden macrophages in induced sputum are a marker of oropharyngeal reflux and possible gastric aspiration”. European Respiratory Journal. 16 (6): 1119–1122. doi:10.1034/j.1399-3003.2000.16f17.x. ISSN 0903-1936.
- ↑ Levade T, Salvayre R, Dongay G, Dang QQ, Vieu C, Bessac A; et al. (1987). “Chemical analysis of the bronchoalveolar washing fluid in the diagnosis of liquid paraffin pneumonia”. J Clin Chem Clin Biochem. 25 (1): 45–8. PMID 3559482.
- ↑ Gattuso P, Reddy VB, Castelli MJ (1991). “Exogenous lipoid pneumonitis due to Vicks Vaporub inhalation diagnosed by fine needle aspiration cytology”. Cytopathology. 2 (6): 315–6. PMID 1801953.
- ↑ Ferretti, Gilbert R.; Jankowski, Adrien; Rodière, Mathieu; Brichon, Pierre Yves; Brambilla, Christian; Lantuejoul, Sylvie (2008). “CT-guided Biopsy of Nonresolving Focal Air Space Consolidation”. Journal of Thoracic Imaging. 23 (1): 7–12. doi:10.1097/RTI.0b013e3181453e04. ISSN 0883-5993.
- ↑ Kuroyama, Muneyoshi; Kagawa, Hiroyuki; Kitada, Seigo; Maekura, Ryoji; Mori, Masahide; Hirano, Hiroshi (2015). “Exogenous lipoid pneumonia caused by repeated sesame oil pulling: a report of two cases”. BMC Pulmonary Medicine. 15 (1). doi:10.1186/s12890-015-0134-8. ISSN 1471-2466.
- ↑ Betancourt, Sonia L.; Martinez-Jimenez, Santiago; Rossi, Santiago E.; Truong, Mylene T.; Carrillo, Jorge; Erasmus, Jeremy J. (2010). “Lipoid Pneumonia: Spectrum of Clinical and Radiologic Manifestations”. American Journal of Roentgenology. 194 (1): 103–109. doi:10.2214/AJR.09.3040. ISSN 0361-803X.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
The incidence and prevalence of lipoid pneumonia are underestimated. It is mostly because of similarities between pneumonias from different causes and lack of specific marker to distinguish pneumonias from each other. In 2019 there was an outbreak of vaping based pulmonary complications.
Epidemiology and Demographics
Incidence
- In 2019 there was an outbreak of vaping based pulmonary complications.
- The majority of underlying cause of morbidity was lipoid pneumonia.
- The incidence of cases differentiated based on state can be seen on :“Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping”.
- The incidence and prevalence of lipoid pneumonia are underestimated. It is mostly because of similarities between pneumonias from different causes and lack of specific marker to distinguish pneumonia from each other.[1]
- There is no prediction of incidence of lipoid pneumonia but the incidence of lipoid pneumonia is approximately 300,000 to 600,000 individuals annually in the United States.[2]
Prevalence
- There is no study about prevalence of lipoid pneumonia.
Mortality rate
- Prognosis of lipoid pneumonia is usually indolent, however, it may also be progressive.[3]
- Lipoid pneumonia is not usually a cause of death. Most patients suffer from complications such as superinfection, cor pulmonale or lung cancer which may be mortal.[4][5][6][7]
Age
- Lipoid pneumonia commonly affects children and elderly.[8]
- The incidence of lipoid pneumonia increases with age; the median age at diagnosis is 70-80 years.[9]
Gender
- There is no gender preference in lipoid pneumonia.[10]
References
- ↑ Lanspa, Michael J.; Jones, Barbara E.; Brown, Samuel M.; Dean, Nathan C. (2013). “Mortality, morbidity, and disease severity of patients with aspiration pneumonia”. Journal of Hospital Medicine. 8 (2): 83–90. doi:10.1002/jhm.1996. ISSN 1553-5592.
- ↑ Marik, Paul E. (2001). “Aspiration Pneumonitis and Aspiration Pneumonia”. New England Journal of Medicine. 344 (9): 665–671. doi:10.1056/NEJM200103013440908. ISSN 0028-4793.
- ↑ Gondouin, A.; Manzoni, Ph.; Ranfaing, E.; Brun, J.; Cadranel, J.; Sadoun, D.; Cordier, J.F.; Depierre, A.; Dalphin, J.C. (1996). “Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France”. European Respiratory Journal. 9 (7): 1463–1469. doi:10.1183/09031936.96.09071463. ISSN 0000-0000.
- ↑ Greenberger PA, Katzenstein AL (1983). “Lipid pneumonia with atypical mycobacterial colonization. Association with allergic bronchopulmonary aspergillosis”. Arch Intern Med. 143 (10): 2003–5. PMID 6625788.
- ↑ Dixon C, Bolivar R, Katz R, McMurtrey M (1985). “Lipoid pneumonia and Mycobacterium fortuitum pulmonary infection: successful treatment with sulfisoxazole”. Tex Med. 81 (3): 57–60. PMID 3983869.
- ↑ Greenaway, T. M.; Caterson, I. D. (1989). “HYPERCALCEMIA AND LIPOID PNEUMONIA”. Australian and New Zealand Journal of Medicine. 19 (6): 713–715. doi:10.1111/j.1445-5994.1989.tb00342.x. ISSN 0004-8291.
- ↑ Casey, James F. (1961). “Chronic Cor Pulmonale Associated with Lipoid Pneumonia”. JAMA. 177 (13): 896. doi:10.1001/jama.1961.03040390010003. ISSN 0098-7484.
- ↑ Lanspa, Michael J.; Peyrani, Paula; Wiemken, Timothy; Wilson, Emily L.; Ramirez, Julio A.; Dean, Nathan C. (2015). “Characteristics associated with clinician diagnosis of aspiration pneumonia: A descriptive study of afflicted patients and their outcomes”. Journal of Hospital Medicine. 10 (2): 90–96. doi:10.1002/jhm.2280. ISSN 1553-5592.
- ↑ Lanspa, Michael J.; Jones, Barbara E.; Brown, Samuel M.; Dean, Nathan C. (2013). “Mortality, morbidity, and disease severity of patients with aspiration pneumonia”. Journal of Hospital Medicine. 8 (2): 83–90. doi:10.1002/jhm.1996. ISSN 1553-5592.
- ↑ Kim, Chang Ho; Kim, Eun Jin; Lim, Jae Kwang; Yoo, Seung Soo; Lee, Shin Yup; Cha, Seung Ick; Park, Jae Yong; Lee, Jaehee (2018). “Comparison of exogenous and endogenous lipoid pneumonia: the relevance to bronchial anthracofibrosis”. Journal of Thoracic Disease. 10 (4): 2461–2466. doi:10.21037/jtd.2018.04.06. ISSN 2072-1439.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Lipoid pneumonia pathogenicity is because of lipid aspiration. Common risk factors in the development of aspiration pneumonia include dysphagia, swallowing dysfunction, altered mental status, COPD, and hospitalization. Less common risk factors in the development of aspiration pneumonia include medications, esophageal motility disorders, vomiting, enteral feeding, oropharyngeal colonization, male sex, and smoking.
Risk Factors
- Lipoid pneumonia major risk factor is vaping, E-cigarette smoking, occupational (fire eaters) , lipoid laxatives, aspiration pneumonia.
- Common risk factors in the development of aspiration pneumonia include dysphagia, swallowing dysfunction, altered mental status, COPD, and hospitalization.[1][2][3]
- Less common risk factors in the development of aspiration pneumonia include medications, esophageal motility disorders, vomiting, enteral feeding, oropharyngeal colonization, male sex, and smoking.
Common Risk Factors
- Common risk factors of developmentin lipoid pneumonia:[4][5][6][7][8][9][10][11][12]
- The aspiration or inhalation of fatty substances is a central causative factor for exogenous lipoid pneumonia.
- Trivial habits such as use of oil based laxatives, lip balm, lip gloss and petroleum jelly.
- Siphoning of various mineral oils (e.g., diesel) from containers.
- Traditional folk remedies such as the use of oily nasal drops.
- Forceful animal fat feeding, such as ‘ghee’, in children to establish regular bowel habits.
- Trans nasal prescriptions of oil based drugs to treat cough and cold.
- Iatrogenic complication following bronchography using the dye propyliodone.
- Common risk factors in the development of aspiration pneumonia include:
- Dysphagia from neurologic diseases such as:
- Swallowing dysfunction
- Chronic obstructive pulmonary disease (COPD)
- Hyperinflation
- Altered mental status
- Acute alcohol abuse
- Seizures
- Hospitalization
- Nursing home residents
Less Common Risk Factors
- Less common risk factors in the development of aspiration pneumonia include:
- Medications such as:
- Esophageal motility disorders such as
- Vomiting
- Anesthesia induction
- Enteral feeding
- Oropharyngeal colonization
- Poor oral hygiene
- Smoking
- Diabetes mellitus
References
- ↑ DiBardino, David M.; Wunderink, Richard G. (2015). “Aspiration pneumonia: A review of modern trends”. Journal of Critical Care. 30 (1): 40–48. doi:10.1016/j.jcrc.2014.07.011. ISSN 0883-9441.
- ↑ Taylor, Joanne K.; Fleming, Gillian B.; Singanayagam, Aran; Hill, Adam T.; Chalmers, James D. (2013). “Risk Factors for Aspiration in Community-acquired Pneumonia: Analysis of a Hospitalized UK Cohort”. The American Journal of Medicine. 126 (11): 995–1001. doi:10.1016/j.amjmed.2013.07.012. ISSN 0002-9343.
- ↑ Hu, Xiaowen; Lee, Joyce S.; Pianosi, Paolo T.; Ryu, Jay H. (2015). “Aspiration-Related Pulmonary Syndromes”. Chest. 147 (3): 815–823. doi:10.1378/chest.14-1049. ISSN 0012-3692.
- ↑ Gondouin, A.; Manzoni, Ph.; Ranfaing, E.; Brun, J.; Cadranel, J.; Sadoun, D.; Cordier, J.F.; Depierre, A.; Dalphin, J.C. (1996). “Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France”. European Respiratory Journal. 9 (7): 1463–1469. doi:10.1183/09031936.96.09071463. ISSN 0000-0000.
- ↑ Spickard, Anderson (1994). “Exogenous Lipoid Pneumonia”. Archives of Internal Medicine. 154 (6): 686. doi:10.1001/archinte.1994.00420060122013. ISSN 0003-9926.
- ↑ Seaton, A. (2010). “Lipoid pneumonia in a fire breather”. Occupational Medicine. 60 (5): 406–406. doi:10.1093/occmed/kqq094. ISSN 0962-7480.
- ↑ Kitchen, J M; O’Brien, D E; McLaughlin, A M (2008). “Perils of fire eating”. Thorax. 63 (5): 401–401. doi:10.1136/thx.2007.090001. ISSN 0040-6376.
- ↑ Meltzer, E.; Guranda, L.; Perelman, M.; Krupsky, M.; Vassilenko, L.; Sidi, Y. (2005). “Lipoid pneumonia: A preventable form of drug-induced lung injury”. European Journal of Internal Medicine. 16 (8): 615–617. doi:10.1016/j.ejim.2005.06.014. ISSN 0953-6205.
- ↑ Gurell, Michael N.; Kottmann, R. Matthew; Xu, Haodong; Sime, Patricia J. (2008). “Exogenous Lipoid Pneumonia: An Unexpected Complication of Substance Abuse”. Annals of Internal Medicine. 149 (5): 364. doi:10.7326/0003-4819-149-5-200809020-00027. ISSN 0003-4819.
- ↑ Hadda, Vijay; Khilnani, Gopi C; Bhalla, Ashu S; Mathur, Sandeep (2009). “Lipoid pneumonia presenting as non resolving community acquired pneumonia: a case report”. Cases Journal. 2 (1): 9332. doi:10.1186/1757-1626-2-9332. ISSN 1757-1626.
- ↑ McDonald, John R.; Hodgson, Corrin H. (1954). “The Problem of Lipoid Pneumonia or Granuloma of the Lung”. Medical Clinics of North America. 38 (4): 989–996. doi:10.1016/S0025-7125(16)34825-8. ISSN 0025-7125.
- ↑ Wolfson, B. J.; Allen, J. L.; Panitch, H. B.; Karmazin, N. (1989). “Lipid aspiration pneumonia due to gastroesophageal reflux”. Pediatric Radiology. 19 (8): 545–547. doi:10.1007/BF02389570. ISSN 0301-0449.
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
There is insufficient evidence to recommend routine screening for lipoid pneumonia.
Screening
- There is insufficient evidence to recommend routine screening for lipoid pneumonia..[1]
References
- ↑ Wright BA, Jeffrey PH (1990). “Lipoid pneumonia”. Semin Respir Infect. 5 (4): 314–21. PMID 2093976.
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Patients might present acutely with inflammation and cough, fever, and dyspnea. However, they might be asymptomatic and present with an incidental mass on radiographs. Due to its nonspecific symptoms and radiological features, lipoid pneumonia often remains undiagnosed or diagnosis is delayed. The oil released illicits a giant-cell granulomatous reaction (hence also called lipid granulomatosis), chronic inflammation, and alveolar and interstitial fibrosis. Evolution of lesions with time has been described: Fresh lesions show alveolar infiltration by lipid-laden macrophages and almost normal alveolar walls and septa, and advanced lesions show larger vacuoles and inflammatory infiltrates in alveolar walls, bronchial walls and septa.
Natural History, Complications, and Prognosis
- Patients might present acutely with inflammation and cough, fever, and dyspnea. However, they might be asymptomatic and present with an incidental mass on radiographs.[1][2]
- Due to its nonspecific symptoms and radiological features, lipoid pneumonia often remains undiagnosed or diagnosis is delayed.
- The oil released illicits a giant-cell granulomatous reaction (hence also called lipid granulomatosis), chronic inflammation, and alveolar and interstitial fibrosis.
- Evolution of lesions with time has been described:[3][4][5]
- Fresh lesions show alveolar infiltration by lipid-laden macrophages and almost normal alveolar walls and septa.
- Advanced lesions show larger vacuoles and inflammatory infiltrates in alveolar walls, bronchial walls and septa.
References
- ↑ Guerguerian, Anne-Marie; Lacroix, Jacques (2000). “Pulmonary injury after intravenous hydrocarbon injection”. Paediatrics & Child Health. 5 (8): 471–472. doi:10.1093/pch/5.8.471. ISSN 1205-7088.
- ↑ Domej, Wolfgang; Mitterhammer, Heike; Stauber, Rudolf; Kaufmann, Peter; Smolle, Karl Heinz (2007). “Successful outcome after intravenous gasoline injection”. Journal of Medical Toxicology. 3 (4): 173–177. doi:10.1007/BF03160935. ISSN 1556-9039.
- ↑ Burke, M; Fraser, R (1988). “Obstructive pneumonitis: a pathologic and pathogenetic reappraisal”. Radiology. 166 (3): 699–704. doi:10.1148/radiology.166.3.3340764. ISSN 0033-8419.
- ↑ “www.thoracic.org” (PDF).
- ↑ Cohen, Allen B.; Cline, Martin J. (1972). “In VitroStudies of the Foamy Macrophage of Postobstructive Endogenous Lipoid Pneumonia in Man1–3”. American Review of Respiratory Disease. 106 (1): 69–78. doi:10.1164/arrd.1972.106.1.69. ISSN 0003-0805.
Diagnosis
Diagnosis
Diagnostic study of choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Interventions | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
